natgillin/translations-raw huggingface dataset:
and B1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene,cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and 
i B1 zajedno s atomima na koje su priključeni, čine benzen, naftalen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; i
and D1, together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and 
i D1 zajedno s atomima na koje su priključeni, čine benzen, naftalen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; i
is heteroaryl, which is unfused or fused with R3A; R3A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 
A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; je heteroaril koji je nestaljen ili staljen s R3A;
is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with R4A; R4A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 
A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R4A;
R6A and R6B are independently selected alkyl; 
A i R6B su neovisno odabrani od alkila;
is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with R15A; R15A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 
je cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken, od kojih je svaki nestaljen ili staljen s R15A; A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken;
is heteroarene, which is unfused or fused with R24A; R24A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 
je heteroaren koji je nestaljen ili staljen s R24A; A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken;
is heteroarylene, which is unfused or fused with R29A; R29A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 
A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; je heteroarilen koji je nestaljen ili staljen s R29A;
is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with R30A; R30A is benzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 
A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; je cikloalkilen, cikloalkenilen, heterocikloalkilen ili heterocikloalkenilen, od kojih je svaki nestaljen ili staljen s R30A;
is alkyl, which is unsubstituted or substituted with OR67; 
je alkil koji je nesupstituiran ili supstituiran s OR67;
is alkyl, which is unsubstituted or substituted with OR67; 
je alkil koji je nesupstituiran ili supstituiran s R67;
The combination of any one of claims 1 to 19, for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T cell or B cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient. 
Spoj ili terapeutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 6, naznačen/a time, da se upotrebljava u liječenju pacijenta od raka mjehura, raka mozga, raka dojke, raka koštane srži, raka grlića maternice, kronične limfocitne leukemije, kolorektalnog raka, raka jednjaka, hepatocelularnog raka, limfoblastične leukemije, folikularnog limfoma, limfoidne malignosti s izvorištem u T-stanici ili B-stanici, melanoma, mijelogenske leukemije, raka usta, raka jajnika, raka nemalih stanica pluća, mijeloma, raka prostate, raka malih stanica pluća ili raka slezene.
dissolving the neutral phospholipid and the cholesterol in anhydrous ethanol or a mixed solvent of anhydrous ethanol and tert-butyl alcohol to obtain a solution; mixing the solution with a buffer to obtain a mixture; obtaining a crude blank liposome after removing the ethanol from the mixture through a reduced pressure distillation; and obtaining the blank liposome from the crude blank liposome using at least one of a high-pressure homogenizer and an extrusion equipment; 
priprema praznog liposoma prema bilo kojem od sljedećih postupaka A do D: otapanje neutralnog fosfolipida i kolesterola u bezvodnom etanolu ili miješanom otapalu bezvodnog etanola i tert-butil alkohola ovisno o željenoj formulaciji, miješanje smjese s puferom da se dobije sirovi prazni liposom nakon uklanjanja etanola putem destilacije pod sniženim tlakom, i zatim priprema praznog liposoma sa željenom veličinom čestica uporabom opreme homogenizatora s visokim pritiskom i/ili za ekstruziju;
dissolving the neutral phospholipid and the cholesterol in anhydrous ethanol or a mixed solvent of anhydrous ethanol and tert-butyl alcohol to obtain a solution; mixing the solution with a buffer to obtain a mixture; and preparing the blank liposome from the mixture using at least one of a high-pressure homogenizer and an extrusion equipment; 
otapanje neutralnog fosfolipida i kolesterola u bezvodnom etanolu ili miješanom otapalu bezvodnog etanola i tert-butil alkohola ovisno o željenoj formulaciji, miješanje smjese s puferom, i zatim priprema praznog liposoma sa željenom veličinom čestica uporabom opreme homogenizatora s visokim pritiskom i/ili za ekstruziju;
The liposome injection according to claim 5, wherein the injection is a liquid injection or a lyophilized powder for injection. 
Injekcija liposoma prema zahtjevu 13, naznačena time što je ta injekcija tekuća injekcija ili liofilizirani prašak za injekciju.
The liposome injection according to claim 5, wherein the injection further comprises an antioxidant selected from the group consisting of a water-soluble antioxidant and an oil-soluble antioxidant; wherein the oil-soluble antioxidant is selected from the group consisting of a-tocopherol, a-tocopherol succinate, a-tocopherol acetate and a mixture thereof; the water-soluble antioxidant is selected from the group consisting of ascorbic acid, sodium bisulfite, sodium sulfite, sodium pyrosulfite, L-cysteine and a mixture thereof; and the amount of the antioxidant is more than 0% (w/v), but less than or equal to 0.5% (w/v), of the liposome injection. 
Injekcija liposoma prema zahtjevu 13, naznačena time što ta injekcija dalje sadrži antioksidans, pri čemu se taj antioksidans izabire iz skupine koja obuhvaća u vodi topljiv antioksidans i u ulju topljiv antioksidans; gdje se taj u ulju topljiv antioksidans izabire iz skupine koja obuhvaća a-tokoferol, a-tokoferol sukcinat, a-tokoferol acetat i njihove smjese; gdje se taj u vodi topljiv antioksidans izabire iz skupine koja obuhvaća askorbinsku kiselinu, natrijev bisulfit, natrijev sulfit, natrijev pirosulfit, L-cistein i njihove smjese; omjer dodanog antioksidansa je 0 ~ 0,5% (tež/vol), i minimum nije 0%.
The liposome injection according to claim 12, wherein the injection is the lyophilized powder for injection comprising a lyoprotectant, and the lyophilized powder is prepared by freeze-drying. 
Injekcija liposoma prema zahtjevu 15, naznačena time što je ta injekcija liofilizirani prašak za injekciju koji sadrži lioprotektant i priprema se sušenjem putem zamrzavanja.
The compound of claim 1, wherein A is selected from the group consisting of benzothiazole, pyrimidine, pyridine, pyridazine, pyrazine, isoquinoline, quinoline, thiazole, benzimidazole, imidazole, benzoxazole, benzothiophene, thiophene, benzofuran and furan. 
Spoj temeljem zahtjeva 1, naznačen time što je A izabran iz skupine koju čine benzotiazol, pirimidin, piridin, piridazin, pirazin, izokvinolin, kvinolin, tiazol, benzimidazol, imidazol, benzoksazol, benzotiofen, tiofen, benzofuran i furan.
The compound of claim 4, wherein B is selected from the group consisting of thiophene, furan, pyrrole, pyrazole, isoxazole, pyridine, pyrimidine, quinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, indole, imidazole, thiazole, imidazothiazole, benzooxazine and quinoxaline. 
Spoj temeljem zahtjeva 4, naznačen time što je B izabran iz skupine koju čine tiofen, furan, pirol, pirazol, izoksazol, piridin, pirimidin, kvinolin, izokvinolin, tetrahidroizokvinolin, benzotiofen, benzofuran, indol, imidazol, tiazol, imidazotiazol, benzooksazin i kvinoksalin.
The compound of claim 6, wherein D is selected from the group consisting of benzothiazole, pyrimidine, pyridine, pyridazine, pyrazine, isoquinoline, quinoline, thiazole, benzimidazole, imidazole, benzoxazole, benzothiophene, thiophene, benzofuran and furan. 
Spoj temeljem zahtjeva 6, naznačen time što je D izabran iz skupine koju čine benzotiazol, pirimidin, piridin, piridazin, pirazin, izokvinolin, kvinolin, tiazol, benzimidazol, imidazol, benzoksazol, benzotiofen, tiofen, benzofuran i furan.
The compound of any of claims 6 to 8, wherein G is selected from the group consisting of thiophene, furan, pyrrole, pyrazole, isoxazole, pyridine, pyrimidine, quinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, indole, imidazole, thiazole, imidazothiazole, benzooxazine and quinoxaline. 
Spoj temeljem bilo [kojeg od zahtjeva 6 do 8, naznačen time što je G izabran iz skupine koju čine tiofen, furan, pirol, pirazol, izoksazol, piridin, pirimidin, kvinolin, izokvinolin, tetrahidroizokvinolin, benzotiofen, benzofuran, indol, imidazol, tiazol, imidazotiazol, benzooksazin i kvinoksalin.
The use of a compound as claimed in any of claims 1 to 9 for the treatment of depressions and/or bipolar disorders such as, for example, dysthymic disorders, subsyndromal depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic disorders. 
Upotreba spoja temeljem bilo kojeg od zahtjeva 1 do 10, njegovog tautomernog oblika, enantiomernog oblika, dijastereomernog oblika i/ili fiziološki tolerirane soli za pripremu lijeka za liječenje depresija i/ili bipolarnih poremećaja kao što su, na primjer, distimički poremećaji, subsindromalna depresija, poremećaji sa sezonskim učinkom, predmenstrualni disforički poremećaji i/ili psihotični poremećaji.
The use of a compound as claimed in any of claims 1 to 9 for the treatment of anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, post-traumatic disorders, acute stress disorders and/or social phobia. 
Upotreba spoja temeljem bilo kojeg od zahtjeva 1 do 10, njegovog tautomernog oblika, enantiomernog oblika, dijastereomernog oblika i/ili fiziološki tolerirane soli za pripremu lijeka za liječenje tjeskobe i/ili poremećaja povezanih sa stresom kao što su, na primjer, općeniti tjeskobni poremećaji, panični poremećaji, opsesivno-kompulzivni poremećaji, posttraumatski poremećaji, poremećaji uzrokovani akutnim stresom i/ili socijalna fobija.
The use of a compound as claimed in any of claims 1 to 9 for the treatment of memory disorders and/or Alzheimer's disease. 
Upotreba spoja temeljem bilo kojeg od zahtjeva 1 do 10, njegovog tautomernog oblika, enantiomernog oblika, dijastereomernog oblika i/ili fiziološki tolerirane soli za pripremu lijeka za liječenje poremećaja pamćenja i/ili Alzheimerove bolesti.
A method of making a belt-creped absorbent cellulosic sheet (10) the method characterized by: 
Metoda za izradu apsorbirajuće celulozne plohe krepirane remenom (10), metoda obuhvaća:
connecting regions of a relatively low local basis weight; 
spojnim područjima relativno velike lokalne osnovne mase;
drying the wet web (154) to form the absorbent cellulosic sheet (10), wherein the papermaking furnish is selected and the steps of belt-creping, applying the vacuum, and drying are controlled such that the sheet (10) has: 
sušenje mokre strukture (154) zbog oblikovanja apsorbirajuće celulozne plohe (10), pri čemu su odabrana oprema za izradu papira i koraci krepiranja remenom, primjena vakuuma, i sušenje kontrolirani tako da ploha (10) ima:
fiber-enriched hollow domed regions (12) on an upper side of the sheet (10), the domed regions having a relatively high local basis weight; 
vlaknima obogaćena udubinama nadsvođena područja (12) s gornje strane plohe (10), udubinama nadsvođena područja imaju relativno veliku lokalnu osnovnu masu;
connecting regions (18) forming a network interconnecting the domed regions (12), the connecting regions having a relatively low local basis weight; and 
spojna područja (18) koja tvore mrežu koja međusobno spaja nadsvođena područja (12), spojna područja imaju relativno malu lokalnu osnovnu masu; i
transition areas (38) with consolidated fibers that transition from the connecting regions (18) to the domed regions (12). 
prijelazna područja (38) s konsolidiranim vlaknima koja čine prijelaz iz spojnih područja (18) u nadsvođena područja (12).
The method according to claim 1, wherein the creping belt (50) has a non-random pattern of perforations. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu krepirajući remen (50) ima nenasumični uzorak perforacija.
The method according to claim 2, wherein the non-random pattern is a staggered pattern. 
Metoda u skladu s patentnim zahtjevom 2, pri čemu je nenasumični uzorak izmjenični uzorak.
The method according to claim 4, wherein the perforations of the creping belt (50) have oval-shaped openings with major axes aligned in the cross machine direction. 
Metoda u skladu s patentnim zahtjevom 4, pri čemu perforacije krepirajućeg remena (50) imaju otvore ovalnog oblika s glavnom osi poravnatom unakrsno od smjera stroja.
The method according to claim 7, wherein the raised lips (110) have a height above the surrounding areas of the belt of from 10% to 30% of the belt thickness. 
Metoda u skladu s patentnim zahtjevom 7, pri čemu uzdignute usne (110) imaju visinu iznad okolnih područja remena od oko 10% do 30% debljine remena.
The method according to claim 1, wherein the creping belt (50) is of a generally unitary construction made from one of a solid polymer sheet material, a reinforced polymer sheet material, and a filled polymer sheet material. 
Metoda u skladu s jednim od prethodnih patentnih zahtjeva, pri čemu je krepirajući remen (50) uglavnom jednolične konstrukcije načinjene od jednog od čvrstih materijala polimerne plohe, armiranog materijala polimerne plohe i ispunjenog materijala polimerne plohe.
The composition of claim 1 or use of claim 2, wherein the anti-ABCB5 antibody or antigen-binding fragment thereof is a chimeric antibody comprising a variable domain which specifically binds to ABCB5 and a constant domain, wherein the variable domain and the constant domain are from different species. 
Pripravak prema zahtjevu 1 ili uporaba prema zahtjevu 2, naznačen time da anti-ABCB5 protutijelo ili njegov fragment koji veže antigen je kimerno protutijelo koje sadrži varijabilnu domenu koja se specifično veže na ABCB5 i konstantnu domenu, pri čemu su varijabilna domena i konstantna domena od različitih vrsta.
applying an aqueous solution comprising a dissolved salt of Micafungin to a hydrophobic adsorbent resin support; 
primjenu vodene otopine koja sadrži otopljenu sol Micafungina na podlogu od hidrofobne adsorpcijske smole;
eluting the dissolved pharmaceutically acceptable salt of Micafungin with a solution comprising a water miscible organic solvent; 
eluiranje otopljene farmaceutski prihvatljive soli Micafungina s otopinom koja sadrži organsko otapalo koje se miješa s vodom;
provided that at least one of 
pod uvjetom da najmanje jedno od
A method according to claim 12, further comprising a step wherein the bound Micafungin of step b) is further exposed to an aqueous solution comprising a water miscible organic solvent one or more times for the removal of impurities. 
Postupak prema zahtjevu 12, koji dodatno sadrži korak naznačen time da se vezani Micafungin iz koraka b) dodatno jednom ili više puta izlaže vodenoj otopini koja sadrži organsko otapalo koje se miješa s vodom, radi uklanjanja nečistoća.
A method according to claim 4, wherein the aqueous solution comprising a dissolved salt of Micafungin in step a) comprises a water miscible organic solvent in the range of 10 % v/v. 
Postupak prema zahtjevu 4, naznačen time da vodena otopina koja sadrži otopljenu sol Micafungina u koraku a) sadrži organsko otapalo koje se miješa s vodom u rasponu od 10 % v/v.
A method according to claim 6, wherein the aqueous solution in step b) comprises a water miscible organic solvent in the range of 20 % v/v. 
Postupak prema zahtjevu 6, naznačen time da vodena otopina u koraku b) sadrži organsko otapalo koje se miješa s vodom u rasponu od 20 % v/v.
A method according to claim 1, wherein the water miscible organic solvent is selected from the group consisting of branched or non-branched C1-C3 alcohols, C3-C6 ketones and polar aprotic organic solvents. 
Postupak prema zahtjevu 1, naznačen time da je organsko otapalo koje se miješa s vodom odabrano iz skupine koju čine razgranati ili ne-razgranati C1-C3 alkoholi, C3-C6 ketoni i polarna aprotonska organska otapala.
A method according to claim 8, wherein the water miscible organic solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol, acetone and acetonitrile. 
Postupak prema zahtjevu 8, naznačen time da je organsko otapalo koje se miješa s vodom odabrano iz skupine koju čine metanol, etanol, propanol, izopropanol, aceton i acetonitril.
A method according to claim 9, wherein the aqueous solution in step c) comprises at least 30 % v/v acetonitrile as a water miscible organic solvent. 
Postupak prema zahtjevu 9, naznačen time da vodena otopina u koraku c) sadrži najmanje 30 % v/v acetonitrila kao organskog otapala koje se miješa s vodom.
A method according to claim 9, wherein the water miscible organic solvent is methanol. 
Postupak prema zahtjevu 9, naznačen time da organsko otapalo koje se miješa s vodom je metanol.
A method according to claim 11, wherein the aqueous solution in step c) comprises at least 70 % v/v methanol, such as at least 90 %v/v methanol, such as at least 95 % v/v methanol as a water miscible organic solvent. 
Postupak prema zahtjevu 11, naznačen time da vodena otopina u koraku c) sadrži najmanje 70 % v/v metanola, odnosno najmanje 90 %v/v metanola, odnosno najmanje 95 % v/v metanola kao organskog otapala koje se miješa s vodom.
Method according to any of the claims 1-9, 11-13, wherein the pharmaceutically acceptable salt of Micafungin is the sodium salt, and the resin is HP20SS, and the aqueous solution comprising a dissolved salt of Micafungin in step a) comprises Micafungin DIPEA and 10% v/v Methanol, and the solution in step b) comprises 20% v/v Methanol and 80% v/v 3M NaCl, 0.1M NaCH3COO and the solution in step c) comprises 40% v/v Methanol and the solution in step d) comprises 90% v/v Methanol. 
Postupak prema bilo kojem od zahtjeva 1-9, 11-13, naznačen time da farmaceutski prihvatljiva sol Micafungina je natrijeva sol, i smola je HP20SS, te da vodena otopina sadrži otopljenu sol Micafungina u koraku a) sadrži Micafungin DIPEA i 10% v/v Metanola, te otopina u koraku b) sadrži 20% v/v Metanola i 80% v/v 3M NaCl, 0.1M NaCH3COO i otopina u koraku c) sadrži 40% v/v Metanola i otopina u koraku d) sadrži 90% v/v Metanola.
Method according to claim 1, wherein the aqueous solution comprising a dissolved salt of Micafungin in step a) or the aqueous solution in step b) of the present method comprises 2-30% v/v of a water miscible organic solvent. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina sadrži otopljenu sol Micafungina u koraku a) ili vodena otopina u koraku b) prema predmetnom postupku sadrži 2-30% v/v organskog otapala koje se miješa s vodom.
Method according to claim 1, wherein the aqueous solution comprising a dissolved salt of Micafungin in step a) and the aqueous solution in step b) of the present method comprises 2-30% v/v of a water miscible organic solvent. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina sadrži otopljenu sol Micafungina u koraku a) i vodena otopina u koraku b) prema predmetnom postupku sadrži 2-30% v/v organskog otapala koje se miješa s vodom.
Method according to claim 1, wherein the aqueous solution comprising a dissolved salt of Micafungin in step a) and the aqueous solution in step b) of the present method comprises a water miscible organic solvent. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina sadrži otopljenu sol Micafungina u koraku a) i vodena otopina u koraku b) prema predmetnom postupku sadrži organsko otapalo koje se miješa s vodom.
Method according to claim 1, wherein the aqueous solution comprising a dissolved salt of Micafungin in step a) and the aqueous solution in step b) of the present method comprises Methanol. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina sadrži otopljenu sol Micafungina u koraku a) i vodena otopina u koraku b) prema predmetnom postupku sadrži Metanol.
Method according to claim 1, wherein the water miscible organic solvent present in the aqueous solution comprising a dissolved salt of Micafungin in step a) and/or the aqueous solution in step b) is Methanol. 
Postupak prema zahtjevu 1, naznačen time da organsko otapalo koje se miješa s vodom koje se nalazi u vodenoj otopini koja sadrži otopljenu sol Micafungina u koraku a) i/ili vodena otopina u koraku b) je Metanol.
The device according to claim 1 or 2, characterized in that, outside said anchoring regions (5), the section of said core (1) is circular. 
Uređaj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je, izvan navedenih područja sidrenja (5), presjek navedene jezgre (1) kružnog oblika.
The device according to any one of claims 1 to 3, characterized in that said solid core (1) is preferably helically surrounded by a solid element (8) of small section to contribute to the integrity of the polymer and antibiotic layer (7) arranged thereon. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je navedena puna jezgra (1) po mogućnosti helikoidalno okružena punim elementom (8) malog presjeka koji doprinosi cjelovitosti polimera i antibiotskog sloja (7) raspoređenog na njemu.
The device according to claim 4, characterized in that the section of said solid element is circular and/or polygonal. 
Uređaj u skladu s patentnim zahtjevom 4, naznačen time što je presjek navedenog punog elementa kružnog i/ili mnogokutnog oblika.
The device according to claim 4 or 5, characterized in that said solid element is a wire. 
Uređaj u skladu s patentnim zahtjevom 4 ili 5, naznačen time što je navedeni puni element žica.
The method of any one of claims 1 to 5, wherein the evaporated gas phase stream from the devolatization contains at least 30% of lactide, preferably at least 60%, most preferred at least 90%. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da evaporirani tok plinovite faze iz procesa otplinjavanja, sadrži najmanje 30% laktida, poželjno najmanje 60%, a najbolje najmanje 90%.
providing a metal strip as a substrate; 
pribavljanje metalne trake kao supstrata;
providing a polymer film for coating onto the substrate; 
pribavljanje polimernog filma za oblaganje supstrata;
melting a suitable mixture of polymer granules in one or more extruders; 
topljenjem prikladne smjese granula polimera u jednom ili više ekstrudera;
reducing the thickness of the solid polymer film by stretching the solid polymer film in a stretching unit by exerting a stretching force only in the longitudinal direction; 
smanjenjem debljine čvrstog polimernog filma istezanjem čvrstog polimernog filma u jedinici za istezanje pod djelovanjem sile istezanja samo u uzdužnom smjeru;
laminating the stretched polymer film onto the substrate to produce a polymer-coated substrate; 
laminiranjem istegnutog polimernog filma na supstrat da bi se proizveo polimerom obloženi supstrat;